Cyternex is a privately held biotechnology company developing novel small molecule anticancer agents for patients with advanced disease. Founded in 1998, Cyternex is investigating the role of 3-D DNA structures in the regulation of known cancer genes and other aspects of tumor biology. By targeting these unique structures, Cyternex is developing drug candidates to regulate oncogene expression. Cyternex's initial product portfolio is based on research conducted by Dr. Laurence Hurley at The University of Texas at Austin. Cyternex has commercial rights to one issued U.S. patent and has several U.S. and foreign patents pending.
http://www.moleculartemplates.com
Molecular Templates Inc. is creating an entirely new generation of potent anti-cancer agents based on proprietary applied proteomics technologies. The novel therapeutic agents in development by MTI are aimed particularly at melanoma, prostate and other metastatic cancers. Such agents are derived from the sophisticated mutation and selection of Shiga-like toxin (SLT) variants using recombinant DNA and proprietary ‘applied proteomics' technologies. New SLT therapeutic agents are created via a systematic approach involving the generation of a large number of mutant SLT genetic sequences that form a permanent combinatorial DNA library. From the library, SLT mutant genes are expressed and the corresponding protein toxins are screened for their ability to kill cancer cell-lines, whilst leaving normal human cell-lines unharmed. Such therapeutic agents have potential advantages for aggressive metastatic cancers that spread to multiple sites in the body, in addition to specific tumour cell-killing capacity. Other uses of derived molecular species, including the DNA libraries themselves, are part of MTI's business objectives. Molecular Templates Inc. aims to advance the pre-clinical and clinical development of novel treatments for melanoma, prostate and other cancers and move rapidly into clinical trials. MTI conducts R&D operations from its laboratory at the University Health Network: Telephone: Facsimile: 416 946 2967 416 946 6529 For MTI business contact information, click here.
http://www.systems-medicine.com
Systems Medicine, Inc. (SMi) develops oncology products by integrating predictive cellular pharmacogenomics ("omics") with world-class clinical and regulatory expertise. This allows SMi to develop patient-selective therapies by defining the "context-of-vulnerability" of cancer and treating only those patients most likely to respond to specific drugs or drug combinations. The Company's business plan is to acquire clinical stage products, assess the context-of-vulnerability for those drugs, and optimally position those drugs for success in clinical development and commercial use.
Insert Therapeutics is focused on designing, developing and commercializing delivery-enhanced therapeutics using our patented class of polymeric delivery systems, which we have called our " CyclosertÔ " family of linear cyclodextrin-containing polymers. We are developing proprietary CyclosertÔ -drug conjugates using off-patent compounds that have documented efficacy, but which also have known issues relating to their solubility, stability, undesirable side effects or poor pharmacokinetics that we can improve significantly with CyclosertÔ . Insert was founded in February 2000 and is headquartered in Pasadena, California. Insert is a majority-owned subsidiary of Arrowhead Research Corporation.
Pharminox was formed in 2002 as a spin-out from Oxford University. We are focused on the discovery and development of novel small molecule drugs for the treatment of cancer. In early 2004, Malcolm Stevens, Director of the Cancer Research UK Experimental Cancer Chemotherapy Group, joined Pharminox as Chief Scientific Officer. Our discovery activities are now based at our new laboratories at the BioCity facility in the centre of Nottingham. We have world class expertise in medicinal chemistry and our approach to drug discovery is very much chemistry-driven. We are progressing a number of innovative discovery programmes which include completely new classes of anti-cancer agent with novel mechanisms of action, offering the prospect of first in class compounds. Over time we intend to build our pipeline through continuing internal drug discovery combined with selective acquisition of appropriate external research and development opportunities. Our in-licensing activities are intended to identify late stage discovery and early stage clinical development programmes which can complement our own internal activities, thus creating an innovative drug development portfolio ranging from early stage discovery through to clinical proof of concept. We have an experienced management team, led by Peter Worrall, with the expertise and collaborative network to undertake, on a virtual basis, the complicated process of drug development. With our people and our portfolio we believe that we have in place the building blocks to become a major force in oncology research and development within the UK over the next few years.
AmpliMed® Corporation is a University of Arizona-based, Arizona Board of Regents-approved pharmaceutical company, located in Tucson, Arizona. It was founded in 1989 with the support of The University of Arizona Technology Development Corporation to discover, develop and commercialize novel compounds for the treatment of cancer. The company was formed by senior faculty members at the Arizona Cancer Center (AZCC) in Tucson, Arizona. The company's anticancer drugs exhibit novel mechanisms of action designed to overcome some of the limitations, such as myelosuppression (suppression of the blood counts), multi-drug resistance (MDR is treatment-induced resistance to many cancer drugs) and other toxicities associated with some current cancer therapy. The company's lead drug, Amplimexon® (imexon, inj.) is effective at killing cancer cells as a result of a unique mechanism of action that results in the buildup of toxic substances inside cancer cells exposed to the drug, ultimately resulting in a process known as apoptosis, or controlled cell death.
ZIOPHARM Oncology, Inc. (ZIOPHARM), incorporated in September 2003, is a development-stage biopharmaceutical company. The Company focuses on developing and commercializing a portfolio of in-licensed cancer drugs that address unmet medical needs. The Company is focused on licensing and developing drug candidate families that are related to cancer therapeutics on the market or in development and that can be developed in intravenous (IV) and/or oral forms of administration. As of December 31, 2007, it was in Phase I and Phase I/II studies for two product candidates known as darinaparsin (ZIO-101), palifosfamide (ZIO-201) and indibulin (ZIO-301). (Source: 10KSB)
Peplin, Inc. is a development-stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products. The Company is developing PEP005 (ingenol mebutate) (PEP005), which is derived from Euphorbia peplus (E. peplus), a plant referred to as petty spurge or radium weed. Its lead product candidate, for which the Company commenced a Phase III clinical trial, is a patient-applied topical gel containing PEP005, a compound used for the treatment of actinic keratosis (AK). The Company is also developing a product candidate containing PEP005 for the treatment of superficial basal cell carcinoma (superficial BCC). This product candidate is in Phase IIa clinical trials and is referred to as PEP005 Gel for BCC. In October 2008, the Company acquired Neosil.
PharmaGap Inc. is a development stage company, principally engaged in drug development and out-licensing of drug compounds. It is a biotechnology company with the main focus on designing and developing therapeutic drugs for the treatment of cancer and other human diseases associated with the human Protein Kinase C enzyme (PKC). Using its drug development platform, the Company is developing a pipeline of compounds targeting PKC. PKC is expressed in abnormal levels in many types of cancer and other diseases, such as diabetes. As of December 31, 2007, the Company’s lead drug compound, PhGa1, was in the pre-clinical testing stage, and had shown in vitro and in vivo efficacy in selected cancer types. (Source: ARS)
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. TreandaÔ, also designated as SDX-105, our lead product candidate, has been marketed by others in Germany for many years, primarily for the treatment of several blood cancers. Building upon this European clinical experience, we are currently conducting Phase II clinical trials for TreandaÔ in the U.S. and Canada and plan to enter Phase III in Q3, 2005 for non-Hodgkin's lymphoma (NHL). SDX-101 is in Phase II development for chronic lymphocytic leukemia (CLL) . We believe that the hematology/oncology market is attractive because of its size, growth rate and rapid adoption of new drugs. Approval by the FDA in this category generally has been based on objective response rates and duration of responses rather than demonstration of survival benefit. As a result, trials of drugs for hematologic malignancies have generally involved fewer patients than trials of drugs for solid tumor indications. The U.S. market for drugs to treat hematologic malignancies which we intend to address has experienced dramatic growth with the approval of agents such as Rituxan®, Campath® and Velcade®, and was greater than ,1.7 billion in 2003. According to Decision Resources, a market research firm, the U.S. market for therapeutics for treatment of NHL, alone is projected to grow by 11, annually through 2010. We have identified promising compounds which have prior human clinical experience by taking advantage of our expertise in clinical research and cancer drug development. By applying our unique insights about these product candidates, and the results of the prior clinical trials and the investments of others, we aim to streamline our product development and optimize our market opportunity. Our product pipeline consists of clinical product candidates and two pre-clinical programs.
Bioenvision's primary focus is the acquisition, development, distribution and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Evoltra(TM), Modrenal(R) (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products. Bioenvision is also developing anti-infective technologies, including the OLIGON(R) technology, an advanced biomaterial that has been incorporated into various FDA approved medical devices.
Aptamera, Inc. is a privately held biotechnology company formed in 2001 to discover, develop and commercialize drugs for the treatment of cancer. The Company is actively pursuing DNA aptamers and small molecule drugs designed to attack cancer cells by interacting with novel molecular targets involved in cancer cell proliferation. Aptamera's lead investigational drug, AGRO100, is an anti-nucleolin aptamer and is currently being administered to patients with advanced solid tumors in Phase I clinical trials.
Aegera is committed to conducting rigorous clinical trials that demonstrate the safety and efficacy of our product candidates. We design our trials to provide us with the most robust and relevant data to understand how our products can have the most meaningful impact in the most appropriate patients. If you are a patient or clinician and would like further information regarding any Aegera clinical trial, please contact the respective trial sites.
Genitope Corporation is a development-stage enterprise focused on the research and development of immunotherapies for the treatment of cancer. Until the recent suspension of the development program, the Company's lead product candidate was MyVax personalized immunotherapy (MyVax), indicated for follicular B-cell non-Hodgkin’s Lymphoma (NHL). Genitope has also been developing a panel of monoclonal antibodies that potentially represents an additional , personalized approach for treating NHL. The monoclonal antibodies might reduce or eliminate the need for chemotherapy in the early treatment of NHL. As of December 31, 2007, the Company is evaluating its strategic alternatives with respect to all aspects of its business. (Source: 10-K)
http://www.oncolyticsbiotech.com
Oncolytics Biotech Inc. is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is in the research and development stage on one product, REOLYSIN, for human application. Its products under development have never been manufactured on a commercial scale. The Company’s potential product for human use, REOLYSIN, is developed from the reovirus. (Source: 20-F)
Progen Pharmaceuticals Limited (Progen) is an Australia-based company. During the fiscal year ended June 30, 2008 (fiscal 2008), the principal activities of the Company were discovery, research and development of biopharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and assurance of biological products. The product platforms include Epigenetics, Angiogenesis and Cell Proliferation. On July 2, 2008, the Company spun-out its manufacturing business as a wholly owned subsidiary company, PharmaSynth Pty Ltd (PharmaSynth). PharmaSynth is focused on the provision of contract pharmaceutical manufacturing services. On July 23, 2008, the Company discontinued the PI-88 phase III study in liver cancer (the PATHWAY trial). In February 2008, the Company completed the acquisition of the United States-based biotechnology company CellGate, Inc.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory